Lamotrigine-induced rash--worth a rechallenge

Area of Science:

• Neurology
• Pharmacology
• Dermatology

Background:

• Lamotrigine (LTG) is an antiepileptic drug (AED) with a favorable efficacy/tolerability profile.
• Rash is the primary serious adverse event associated with LTG treatment.
• Evaluating LTG rechallenge after rash is crucial for patient management.

Purpose of the Study:

• To assess the safety and efficacy of rechallenging patients with lamotrigine (LTG) after experiencing an initial rash.
• To establish a successful protocol for LTG rechallenge.
• To investigate risk factors, such as concurrent valproate use and patient demographics, for rash development during LTG rechallenge.

Main Methods:

• A cohort of 688 patients with epilepsy (idiopathic generalized or focal) were treated with LTG.
• Patients who developed LTG-induced rash were considered for rechallenge using a specific slow-titration schedule.
• The rechallenge protocol involved starting at 5 mg/day, gradually increasing to 25 mg/day over 14-day intervals, followed by standard guideline-based titration.

Main Results:

• Out of 688 patients, 52 (7.6%) developed a rash, with 12 (1.8%) experiencing a rash coincidentally.
• Nineteen patients were rechallenged with LTG, achieving an 84% success rate.
• Concurrent valproate (VPA) use did not increase rash risk during rechallenge, and women were more likely to develop rash (P < 0.009).

Conclusions:

• This study presents the first validated protocol for successful lamotrigine (LTG) rechallenge following drug-induced rash.
• The established rechallenge regimen is effective and safe, with a high success rate.
• Concurrent valproate use is not a contraindication for LTG rechallenge, and female gender is associated with a higher incidence of rash.